Advertisement

World Journal of Urology

, Volume 37, Issue 5, pp 873–878 | Cite as

Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis

  • Niall F. DavisEmail author
  • G. S. Jack
  • W. P. Witjes
  • A. Bjartell
  • C. Caris
  • A. Patel
  • A. de la Taille
  • N. Lawrentschuk
  • D. M. Bolton
  • A. Tubaro
Original Article

Abstract

Purpose

A cost minimisation analysis compares the costs of different interventions’ to ascertain the least expensive over time. We compared different prostate targeted drug treatments with TURP to identify the optimal cost saving duration of a medical therapy for symptomatic benign prostatic enlargement (BPE).

Methods

The Evolution registry is a prospective, multicentre registry, conducted by the European Association of Urology Research Foundation (EAUrf) for 24 months in 5 European countries. Evolution was designed to register the management of symptomatic BPE in clinical practice settings in 5 European countries. Direct cost evaluation associated with prostate targeted medical therapies and TURP was also recorded and analysed.

Results

In total, 1838 men were enrolled with 1246 evaluable at 24 months. Medical therapies were more cost saving than TURP for treatment durations ranging from 2.9 to 70.4 years. Cost saving depended on both medication class and individual country assessed. Daily tamsulosin monotherapy was more cost saving than TURP for ≤ 13.9 years in Germany compared to ≤ 32.7 years in Italy. Daily finasteride monotherapy was more cost saving for ≤ 5.9 years in France compared to ≤ 36.9 years in Spain. Combination therapy was more cost saving for ≤ 5.9 years for Italian patients versus ≤ 13.8 years in Germany.

Conclusions

BPE medical management was more cost saving than TURP for different specific treatment durations. Information from this study will allow clinicians to convey medical and surgical costs over time, to both patients and payors alike, when considering BPE treatment.

Keywords

Benign prostatic enlargement BPE Benign prostatic hyperplasia BPH Cost minimisation analysis 

Abbreviations

BPE

Benign prostatic enlargement

CC

Comorbidities

TURP

Transurethral resection of the prostate

Notes

Author contributions

ND: Data collection, Data analysis, Manuscript writing; GJ: Data analysis, Manuscript writing; WW: Data collection, Manuscript editing; AB: Project development, Manuscript editing; CC: Data collection, Manuscript editing; AP: Data collection, Manuscript editing; AT: Data collection, Manuscript editing; DB: Project development, Manuscript editing; AT: Data analysis, Project development, Manuscript editing.

Funding

The Evolution registry was supported by a restricted Grant from GlaxoSmithKline© (GSK).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Statement of human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standard.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Albisinni S, Biaou I, Marcelis Q, Aoun F, De Nunzio C, Roumeguère T (2016) New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urol 16(1):58Google Scholar
  2. 2.
    Schauer I, Madersbacher S (2015) Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 25(1):6–11Google Scholar
  3. 3.
    Chughtai B, Forde JC, Thomas DDM, Laor L, Hossack T, Woo HH et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Prim 2:16031Google Scholar
  4. 4.
    Heaney LG, Mcallister D, Macmahon J (1999) Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines cost effective? BMJ 319(7201):19–23Google Scholar
  5. 5.
    Greß S (2007) Private health insurance in Germany: consequences of a dual system. Healthc Policy 3(2):29–37Google Scholar
  6. 6.
    Djavan B (2004) 1-Adrenoceptor antagonists for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): state of the art. Eur Urol Suppl 3(4):23–30Google Scholar
  7. 7.
    Lepor H (2007) Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 9(4):181–190Google Scholar
  8. 8.
    Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C (1996) Safety profile of 3 months’ therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 29(1):29–35Google Scholar
  9. 9.
    Roehrborn CG, Rosen RC (2008) Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging 3(3):511–524Google Scholar
  10. 10.
    Nickel JC, Sander S, Moon TD (2008) A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62(10):1547–1559Google Scholar
  11. 11.
    Rittmaster RS, Norman RW, Thomas LN, Rowden G (1996) Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 81(2):814–819Google Scholar
  12. 12.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179(2):616–621Google Scholar
  13. 13.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123–131Google Scholar
  14. 14.
    Keating GM (2012) Dutasteride/tamsulosin: in benign prostatic hyperplasia. Drugs Aging 29(5):405–419Google Scholar
  15. 15.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338(9):557–563Google Scholar
  16. 16.
    Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C et al (2016) EAU Guidelines the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology, pp 1–70Google Scholar
  17. 17.
    Mcvary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803Google Scholar
  18. 18.
    McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398Google Scholar
  19. 19.
    Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ et al (2014) Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results. BJU Int 113(4):623–635Google Scholar
  20. 20.
    Cornu JN, Ahyai S, Bachmann A, De La Rosette J, Gilling P, Gratzke C et al (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67(6):1066–1096Google Scholar
  21. 21.
    Rieken M, Bachmann A, Shariat SF (2015) Long-term follow-up data more than 5 years after surgical management of benign prostate obstruction: who stands the test of time? Curr Opin Urol 26(1):22–27Google Scholar
  22. 22.
    Smith RD, Patel A (2011) Transurethral resection of the prostate revisited and updated. Curr Opin Urol 21(1):36–41Google Scholar
  23. 23.
    Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50(5):969–979Google Scholar
  24. 24.
    Mayer EK, Kroeze SGC, Chopra S, Bottle A, Patel A (2012) Examining the “gold standard”: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int 110(11):1595–1601Google Scholar
  25. 25.
    Fagerström T, Nyman CR, Hahn RG (2011) Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate. J Endourol 25(6):1043–1049Google Scholar
  26. 26.
    Emberton M, Neal DE, Black N, Harrison M, Fordham M, McBrien MP et al (1995) The national prostatectomy audit: the clinical management of patients during hospital admission. Br J Urol 75(3):301–316Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Niall F. Davis
    • 1
    Email author
  • G. S. Jack
    • 1
  • W. P. Witjes
    • 2
  • A. Bjartell
    • 2
    • 3
  • C. Caris
    • 2
  • A. Patel
    • 4
  • A. de la Taille
    • 5
  • N. Lawrentschuk
    • 1
  • D. M. Bolton
    • 1
  • A. Tubaro
    • 6
  1. 1.Department of UrologyThe Austin HospitalMelbourneAustralia
  2. 2.EAU Research FoundationArnhemThe Netherlands
  3. 3.Department of UrologyLund University, Skane HospitalMalmöSweden
  4. 4.Department of UrologySpire London East HospitalIlfordUK
  5. 5.Department of UrologyAssistance Publique des Hopitaux de ParisCréteilFrance
  6. 6.Department of UrologySant’Andrea Hospital, Sapienza University of RomeRomeItaly

Personalised recommendations